
## **Trustees’ Annual Report for the period** 

**From 31 Oct 2021    Period start date   To 30 Oct 2022     Period end date** 

## **Charity name: Lipodystrophy UK** 

**Charity registration number:** 1175462 

## **Objectives and Activities** 

||SORP reference||
|---|---|---|
|Summary of the purposes of<br>the charity as set out in its<br>governing document|Para 1.17|The objects of the CIO are:<br>i.<br>To raise awareness of Lipodystrophy<br>conditions, both within the medical<br>profession and the general public;<br>ii.<br>To provide information and support to<br>people with Lipodystrophy and those<br>affected by it;<br>iii.<br>To advocate for excellent care and<br>improved treatment options for people<br>with Lipodystrophy;<br>To encourage research addressing the<br>concerns of people with Lipodystrophy|
|Summary of the main<br>activities in relation to those<br>purposes for the public<br>benefit, in particular, the<br>activities, projects or<br>services identified in the<br>accounts.|Para 1.17 and<br>1.19|- Patient pathways survey for patients and<br>formal presentation of findings<br>- Patient support activities online<br>- Raising awareness (World Lipodystrophy<br>Day, conferences, publications, social<br>media, focus groups)<br>- Developed a ‘Charity Strategic Plan’<br>- Fatigue project with PLRH started<br>recruiting patients<br>- New website launched|
|Statement confirming<br>whether the trustees have<br>had regard to the guidance<br>issued by the Charity<br>Commission on public<br>benefit|Para 1.18|All trustees have had regard to the Charity<br>Commission’s guidance on public benefit.|



## **Additional information (optional)** 

## You may choose to include further statements where relevant about: 

||<br>SORP reference||
|---|---|---|
|Policy on grant making|Para 1.38|Lipodystrophy UK does not have a policy<br>on grant making, since we don’t currently<br>offer grants|
|Policy on social investment|Para 1.38|Lipodystrophy UK does not have a policy<br>on social investment|





|including program related<br>investment|||
|---|---|---|
|Contribution made by<br>volunteers|Para 1.38|Lipodystrophy UK does not have a policy<br>on contributions made by volunteers|
|Other|||



## **Achievements and Performance** 

||SORP reference||
|---|---|---|
|Summary of the main<br>achievements of the charity,<br>identifying the difference the<br>charity’s work has made to<br>the circumstances of its<br>beneficiaries and any wider<br>benefits to society as a<br>whole.|Para 1.20|1) Ongoing virtual support for community<br>through COVID - live chats, community<br>check-ins, etc.<br>2) Ongoing awareness activities – World<br>Lipodystrophy Day. Applying for funding<br>to organise a Patient Support Day for<br>WLD 2023<br>3) Patient Pathways survey launched for<br>patients. Data combined with Clinician<br>data and findings formally presented at<br>the annual ECLip conference<br>4) New website launched. PO Box set up.<br>5) Fatigue project (in collaboration with the<br>Patient Lead Research Hub, PLRH, and<br>Addenbrookes Hospital): LiFE study<br>focus group conducted and REC<br>approval received. Patient interviews<br>started<br>6) FaceBook charity donations/fundraising<br>set up<br>7) Collaboration with Physicians and<br>Pharma on development of a<br>‘Lipodystrophy scoring tool’ for clinicians<br>8) Chair gave several awareness talks at<br>different conferences and participated in<br>focus groups with stakeholders<br>9) Ongoing relationship with National<br>Centre of Excellence in Lipodystrophy<br>(Addenbrookes Hospital)<br>10) Ongoing patient representative on<br>ECLip Board (re-elected)<br>11) Ongoing relationship with the Centre of<br>Appearance Research (CAR)<br>12) Note: several activities<br>delayed/postponed due to COVID|



**Additional information (optional)** You may choose to include further statements where relevant about: Ongoing objectives to 1) raise awareness of Lipodystrophy conditions; 2) provide 



|Achievements against<br>objectives set|Para 1.41|information and support to people affected<br>by Lipodystrophy; advocate for excellent<br>care and improved treatment options;<br>encourage research addressing the<br>concerns of people with Lipodystrophy|
|---|---|---|
|Performance of fundraising<br>activities against objectives<br>set|Para 1.41|N/A|
|Investment performance<br>against objectives|Para 1.41|N/A|
|Other|||





## **Financial Review** 

|**Financial Review**|||
|---|---|---|
|Review of the charity’s<br>financial position at the end<br>of the period|Para 1.21|Low fundraising income, although sufficient<br>to cover charity expenditure|
|Statement explaining the<br>policy for holding reserves<br>stating why they are held|Para 1.22|Lipodystrophy UK does not have a<br>reserves policy|
|Amount of reserves held|Para 1.22|N/A|
|Reasons for holding zero<br>reserves|Para 1.22|N/A|
|Details of fund materially in<br>deficit|Para 1.24|N/A|
|Explanation of any<br>uncertainties about the<br>charity continuing as a going<br>concern|Para 1.23|N/A|



|**Additional information (optional)**<br>You may choose to include further statements where relevant about:|**Additional information (optional)**<br>You may choose to include further statements where relevant about:|**Additional information (optional)**<br>You may choose to include further statements where relevant about:|
|---|---|---|
|The charity’s principal<br>sources of funds (including<br>any fundraising)|Para 1.47|Funds exclusively from fundraising<br>activities|
|Investment policy and<br>objectives including any<br>social investment policy<br>adopted|Para 1.46|Lipodystrophy UK does not have an<br>investments policy|
|A description of the principal<br>risks facing the charity|Para 1.46|More fundraising activities will be needed to<br>fund more ambitious projects in the future.<br>Actively recruiting a volunteer Fundraising<br>Officer (although little interest in the role so<br>far).|
|Other|||





## **Structure, Governance and Management** 

|Description of charity’s<br>trusts:|||
|---|---|---|
|Type of governing document<br>(trust deed, royal charter)|Para 1.25|Constitution|
|How is the charity<br>constituted?<br>(e.g unincorporated<br>association, CIO)|Para 1.25|Charitable Incorporated Organisation|
|Trustee selection methods<br>including details of any<br>constitutional provisions e.g.<br>election to post or name of<br>any person or body entitled<br>to appoint one or more<br>trustees|Para 1.25|Apart from the first charity trustees, every<br>trustee must be appointed by a resolution<br>passed at a properly convened meeting of<br>the charity trustees|



## **Additional information (optional)** 

## You may choose to include further statements where relevant about: 

|<br>Policies and procedures<br>adopted for the induction<br>and training of trustees|<br>Para 1.51|<br>N/A|
|---|---|---|
|The charity’s organisational<br>structure and any wider<br>network with which the<br>charity works|Para 1.51|N/A|
|Relationship with any<br>related parties|Para 1.51|Working in partnership with The Centre for<br>Appearance Research (CAR) as a member<br>of the Appearance Collective (AC) -<br>supporting people living with visible<br>differences.|
|Other|||



## **Reference and Administrative details** 

|Charity name|Lipodystrophy UK|
|---|---|
|Other name the charity uses|LDUK-although almost phased out|
|Registered charity number|1175462|
|Charity’s principal address|29 Collington Way,<br>Kingston Bagpuize,<br>Abingdon<br>OX13 5GP|
|||





**Names of the charity trustees who manage the charity** 

|1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**<br>**year**|**Name of person (or body) entitled**<br>**to appoint trustee (ifany)**|
|---|---|---|---|---|
||Rebecca Sanders|Chair|N/A|Rebecca Sanders(Founder)|
||Rachel Sanders|Treasurer|N/A|Rebecca Sanders(Founder)|
||BeckySmith|N/A|N/A|Board majorityvote|
||Siobhan Dunn|N/A|N/A|Board majorityvote|
||Claire Adams|N/A|N/A|Board majorityvote|
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||



– Corporate trustees names of the directors at the date the report was approved **Director name** N/A 

Name of trustees holding title to property belonging to the charity 

|**Trustee name**|**Dates acted if not for whole year**||
|---|---|---|
|N/A|||
||||
||||
||||
||||
||||





## **Funds held as custodian trustees on behalf of others** 

Description of the assets N/A held in this capacity Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets 

## **Additional information (optional)** 

## **Names and addresses of advisers (Optional information)** 

|**Type of**<br>**adviser**|**Name**<br>**Address**|**Name**<br>**Address**|
|---|---|---|
|N/A|||
||||
||||
||||



**Name of chief executive or names of senior staff members (Optional information)** 

N/A 

## **Exemptions from disclosure** 

Reason for non-disclosure of key personnel details 

N/A 

## **Other optional information** 



## **Declarations** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

**Signature(s)** 


**Full name(s)** Rebecca Sanders 

**Position (eg Secretary,** Chair **Chair, etc)** 

**Date** 

31/08/2023 



||**Lipodystrophy UK**<br>|**Lipodystrophy UK**<br>|**Lipodystrophy UK**<br>|**Lipodystrophy UK**<br>|**CC16a**|
|---|---|---|---|---|---|
||**For the period**<br>**from**|Period start date<br>Oct-21|**To**|||
|||||||
|**Section A Receipts and payments**||||||
|**A1 Receipts**<br>Donations<br>**918**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**918**<br>**-**<br>**-**<br>**_Sub total_                               -**<br>**_Total receipts_                       918**<br>**A3 Payments**<br>Insurance<br>**169**<br>Invoices<br>**1,318**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**_Sub total_                        1,487**<br>**-**<br>**-**<br>**_Sub total_                                -**<br>**_Total payments_                    1,487**<br>**_Net of receipts/(payments)_ -                    569**<br>**A5 Transfers between funds**<br>**-**<br>**A6 Cash funds last year end**<br>**7,387**<br>**_Cash funds this year end_                    6,818**<br>**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**_Sub total_**_(Gross income for AR)_<br>**A2 Asset and investment sales,**<br>**(see table).**<br>**A4 Asset and investment**<br>**purchases, (see table)**||**to the nearest £**<br>**Restricted**<br>**funds**|**to the nearest £**<br>**Endowment**<br>**funds**|**Total funds**<br>**to the nearest £**|**Last year**<br>**to the nearest £**|
|||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**918**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**918**|**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
|||||||
|||**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**||
||||||**-**|
||||||**-**|
|||||||
|||**-**|**-**|**918**|**-**|
|||||||
|||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**169**<br>**1,318**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**1,487**|**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
||||||**-**|
|||||||
|||**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**||
|||||||
||||||**-**|
|||||||
|||**-**|**-**|**1,487**|**-**|
|||||||
|||**-**<br>**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**<br>**-**|**-                    569**<br>**-**<br>**7,387**<br>**6,818**|**-**|
||||||**-**|
||||||**-**|
||||||**-**|





## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B3 Investment assets**<br>**B5 Liabilities**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>Signed by one or two trustees on<br>behalf of all the trustees|**Details**<br>Bank account<br>**Details**<br>**Details**<br>**Details**<br>**Details**<br>Signature<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))|**to nearest £**<br>**to nearest £**<br>**6,818**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**6,818**<br>**-**<br>OK<br>OK<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>REBECCA SANDERS<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**|**to nearest £**<br>**Endowment**<br>**funds**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**to nearest £**<br>**Endowment**<br>**funds**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
|||REBECCA SANDERS|8/31/2023|
|||||



